**Ind-Swift Laboratories Limited**
*Registered Office*
SCO 850, Shivalik Enclave,
NAC Manimajra, Sector 13,
Chandigarh – 160101 INDIA
info@indswiftlabs.com
0172-2730503, 2730920, 5061851-53
CIN No. L24232CH1995PLC015553

**Ref: ISLL:CH:2026** **Date: 10th August, 2026**

**The President**
**Corporate Relationship Department**
**BSE Limited**
**Phiroze Jeejeebhoy Towers,**
**25th Floor, Dalal Street,**
**Mumbai 400 001**

**The Vice President,**
**Listing Compliance Department,**
**National Stock Exchange of India Limited,**
**Exchange Plaza, 5th Floor**
**Plot No. C/2, G-Block,**
**Bandra Kurla Complex, Bandra (E),**
**Mumbai 400 051**

**BSE Scrip Code: 532305**

**NSE Symbol: INDSWFTLAB**

**SUB: OUTCOME OF BOARD MEETING**

Dear Sir/Ma'am,

Pursuant to the provisions of Regulation 30 and 33 and any other applicable provisions, if any, of the Securities and Exchange of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (hereinafter "SEBI Listing Regulations") we wish to inform that the Board of Directors of the Company in their meeting held today i.e. Monday, 10th August, 2026, have considered and inter-alia approved the following: -

1. Standalone and Consolidated Un-Audited Financial Results of the Company for the quarter ended June 30, 2026.

   The aforesaid Standalone and Consolidated Unaudited Financial Results, as approved by the Board of Directors, along with the Limited Review Reports issued by the Statutory Auditors of the Company thereon, are enclosed herewith as **Annexure I**.

   The said financial results shall also be made available on the Company's website at Quarterly Results - Ind-Swift Group.

2. Approved the sale of land admeasuring approximately 40 Bighas (approximately 10 acres), situated at Village Behra, Derabassi, Punjab for a total consideration of ₹17.50 Crore. The said land was purchased earlier (informed to exchanges vide disclosure dated 1st October, 2024 and 12th December, 2024) for setting up of a Manufacturing facility. The land is being sold as the same was found unsuitable for setting up of the Finished dosages facility as per the applicable International regulatory/registration requirements.

   The transaction is proposed to be completed over a period of 9 (Nine) months, subject to the terms and conditions of the agreement.

   *The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed as* ***Annexure II.***

The Board Meeting commenced at 03:00 P.M and concluded at 04:30 P.M.

Ind-Swift
Laboratories Limited
One World One Health One Ind-Swift

Ind-Swift Laboratories Limited
Registered Office
SCO 850, Shivalik Enclave,
NAC Manimajra, Sector 13,
Chandigarh – 160101 INDIA
info@indswiftlabs.com
0172-2730503, 2730920, 5061851-53
CIN No. L24232CH1995PLC015553

You are requested to kindly take the same on record.

Thanking you,
For **IND-SWIFT LABORATORIES LTD.**

PARDEEP VERMA Digitally signed by PARDEEP VERMA Date: 2026.08.10 19:02:37 +05'30'

Ind-Swift Laboratories Ltd. CHANDIGARH

**PARDEEP VERMA**
**VP-CORPORATE AFFAIRS &**
**COMPANY SECRETARY**

**Encl: As above**

**CA RATTAN KAUR**
B.Com(H), F.C.A.
DISA (ICAI), FAFD (ICAI)

Annexure I

**RATTAN KAUR & ASSOCIATES**
CHARTERED ACCOUNTANTS
SCF: 1, SECTOR: 20-C
CHANDIGARH: 160020
Mobile: 9501343300
Email:carattan@gmail.com

**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of Ind-Swift Laboratories Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).**

**Review Report to**
**The Board of Directors**
**Ind-Swift Laboratories Ltd**

1. We have reviewed the accompanying statement of unaudited standalone financial results (the "Statement") of Ind-Swift Laboratories Ltd. (the "Company") for the Quarter ended June 30, 2026, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 as amended (the "Listing Regulations").

2. The Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

RATTAN KAUR & ASSOCIATES
Chandigarh
FRN 022513N
CHARTERED ACCOUNTANTS

**CA RATTAN KAUR**
B.Com(H), F.C.A.
DISA (ICAI), FAFD (ICAI)

RATTAN KAUR & ASSOCIATES
CHARTERED ACCOUNTANTS
SCF: 1, SECTOR: 20-C
CHANDIGARH: 160020
Mobile: 9501343300
Email:carattan@gmail.com

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanyng Statement prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Rattan Kaur & Associates**
Chartered Accountants
(Regd No: 022513N)

RATTAN KAUR & ASSOCIATES
Chandigarh
FRN 022513N
CHARTERED ACCOUNTANTS

**Rattan Kaur**
(Partner)
M. No. 513530

**Place:** Gurugram
**Date:** August 10, 2026
**UDIN: 26513530DJKNGP2638**

**IND-SWIFT LABORATORIES LIMITED**

**Regd Office : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh-160101**

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026

CIN L24232CH1995PLC015553

| | | | | Rs. In Lakhs |
|---|---|---|---|---|
| | STANDALONE | | | |
| **Particulars** | Quarter Ended 30.06.2026 | Quarter Ended 31.03.2026 | Quarter Ended 30.06.2025 | Year Ended 31.03.2026 |
| | UnAudited | Audited | UnAudited | Audited |
| **Income from Operations:** | | | | |
| Revenue from operations | 18608.24 | 17270.06 | 15358.33 | 63588.85 |
| Other Income | 762.82 | 221.05 | 899.33 | 4695.52 |
| **Total Income** | 19371.06 | 17491.11 | 16257.66 | 68284.37 |
| **EXPENSES:** | | | | |
| a Cost of Materials Consumed | 8172.64 | 7824.45 | 6444.69 | 27474.17 |
| b.Purchase of stock in Trade | 1326.79 | 725.68 | 866.23 | 3765.84 |
| c.( Increase) /decrease in FG,WIP & stock in trade | (1978.22) | (2063.84) | (184.66) | (2890.74) |
| d. Employee benefit | 3895.35 | 3720.34 | 3200.48 | 13632.80 |
| e.Finance Costs | 70.51 | (243.54) | 115.13 | 140.40 |
| f. Depreciation | 758.31 | 807.74 | 667.68 | 3056.69 |
| g. Other expenditure | 3859.33 | 5033.03 | 4165.57 | 16982.90 |
| **TOTAL EXPENSES** | 16104.71 | 15803.86 | 15275.12 | 62162.06 |
| **Profit(loss) before exceptional Items and Tax** | 3266.35 | 1687.26 | 982.54 | 6122.31 |
| Exceptional Items (Income) /loss | 23.58 | 515.24 | 0.00 | 1100.64 |
| **Profit(loss) before Tax (After exceptional items)** | 3242.77 | 1172.01 | 982.54 | 5021.67 |
| **Tax Expenses :-** | | | | |
| Current Tax | 798.37 | 218.29 | 170.58 | 1306.14 |
| Mat credit Utilisation | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax | 0.00 | (540.15) | 0.00 | (540.15) |
| **Profit/ (Loss) after tax and before share of** | 2444.40 | 1493.87 | 811.96 | 4255.68 |
| **Share of profit (loss) in joint venture** | 0.00 | 0.00 | 0.00 | 0.00 |
| **Profit (+)/ Loss (-) for the period from continuing operations** | 2444.40 | 1493.87 | 811.96 | 4255.68 |
| **Profit (+)/ Loss (-) from discontinuing operations** | 0.00 | 0.00 | 0.00 | 0.00 |
| **Tax Expense of discounting operations** | 0.00 | 0.00 | 0.00 | 0.00 |
| **Profit (+)/ Loss (-) from discontinuing operations(after Tax)** | 0.00 | 0.00 | 0.00 | 0.00 |
| **Net Profit /( Loss) for the period after tax & Exceptional items)** | 2444.40 | 1493.87 | 811.96 | 4255.68 |
| | | | | |
| **Other Comprehensive Income** | | | | |
| A) Items that will not be reclassified to P/L A/c | 0.00 | 87.45 | 0.00 | 87.45 |
| B) items that will be reclassified into P/L A/c | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Comprehensive Income ( Loss) for the period , net of Tax | 0.00 | 87.45 | 0.00 | 87.45 |
| Total Comprehensive Income for the Period | 2444.40 | 1406.42 | 811.96 | 4168.23 |
| Paid up Equity Share Capital(Face Value of Rs. 10/- per Share) | 8696.16 | 8683.66 | 8161.16 | 8683.66 |
| Reserve excluding revaluation reserves | | | | 137069.72 |
| EPS (of Rs. 10/- each) (Not annualised) | | | | |
| Basic | 2.81 | 1.79 | 1.18 | 5.09 |
| Diluted | 2.81 | 1.74 | 1.08 | 4.97 |

FOR IND-SWIFT LABORATORIES LIMITED

Navrattan

Date: 10-08-2026

Place: Panchkula

NAVRATTAN MUNJAL

CHAIRMAN

**CA RATTAN KAUR**
B.Com(H), F.C.A.
DISA (ICAI), FAFD (ICAI)

RATTAN KAUR & ASSOCIATES
CHARTERED ACCOUNTANTS
SCF: 1, SECTOR: 20-C
CHANDIGARH: 160020
Mobile: 9501343300
Email:carattan@gmail.com

**Independent Auditor's Review Report on Quarterly Unaudited Consolidated Financial Results of Ind-Swift Laboratories Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (as amended).**

**Review Report to**
**The Board of Directors**
**Ind-Swift Laboratories Ltd**

1) We have reviewed the accompanying statement of unaudited consolidated financial results (the "Statement") of Ind-Swift Laboratories Ltd. (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "The Group"), its Joint Ventures for the Quarter ended June 30, 2026, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2) The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable.

RATTAN KAUR & ASSOCIATES
Chandigarh
FRN 022513N
CHARTERED ACCOUNTANTS

**CA RATTAN KAUR**
B.Com(H), F.C.A.
DISA (ICAI), FAFD (ICAI)

**RATTAN KAUR & ASSOCIATES**
CHARTERED ACCOUNTANTS
SCF: 1, SECTOR: 20-C
CHANDIGARH: 160020
Mobile: 9501343300
Email:carattan@gmail.com

4) The Statement includes the results of the following entities:

**Subsidiaries**

- Fortune (India) Constructions Ltd.
- MJM Remedies Private Limited
- Ind Swift Laboratories Inc. USA
- ISLL Middle East LLC-FZ
- Ind-Swift India Ltd (Kenya)

**Joint Venture**

- Indis Healthcare LLP
- Capital Strikers LLP

5) Based on our review conducted and procedures performed as stated in Paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6) The accompanying Statement includes unaudited interim financial results and other financial information in respect of:

- 2 subsidiaries, whose unaudited interim financial results and other financial information include total revenue of Rs. 344.72 Lakhs, total net profit before tax of Rs. Rs. 7.17 Lakhs, total comprehensive income of Rs. 7.95 Lakhs, for the quarter ended June 30, 2026 as considered in the Statement whose financial information has not been reviewed by their auditors. The unaudited interim financial results and other financial information of these subsidiaries have been approved and furnished to us by the Holding Company's Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries, is based solely on such unaudited interim financial results and other financial information. According to the information and explanations given to us by Management, these unaudited interim financial results and other financial information are not material to the Group.

- 3 subsidiaries, whose unaudited interim financial results and other financial information include total revenue of Rs. 523.58 Lakhs, total net profit before tax of Rs. 335 Lakhs and Total comprehensive income of Rs. 341.68 Lakhs for the quarter ended June 30, 2026. The

RATTAN KAUR & ASSOCIATES Chandigarh FRN 022513N CHARTERED ACCOUNTANTS

**CA RATTAN KAUR**
B.Com(H), F.C.A.
DISA (ICAI), FAFD (ICAI)

RATTAN KAUR & ASSOCIATES
CHARTERED ACCOUNTANTS
SCF: 1, SECTOR: 20-C
CHANDIGARH: 160020
Mobile: 9501343300
Email:carattan@gmail.com

unaudited interim financial results and other financial information of these subsidiaries have been prepared in accordance with accounting principles generally accepted in their respective countries for statutory purposes and have not been reviewed by their auditors. The Holding Company's management has converted the financial statements of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. According to the information and explanations given to us by Holding Company's Management, these unaudited interim financial results and other financial information are not material to the Group. We have not reviewed these conversion adjustments made by the Holding Company's management. Our conclusion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based solely the conversion adjustments prepared by the management of the Holding Company.

- 2 Joint Ventures, whose unaudited interim financial results and other financial information includes the Group's share of net profit before taxes of Rs. 11.40 Lakhs, for the quarter ended June 30, 2026 respectively. These unaudited interim financial results and other financial information have been approved and furnished to us by Holding Company's management and our conclusion on the Statement, in so far as it relates to the affairs included in respect of these Joint Ventures, is based solely on such unaudited financial statements and other financial information. According to the information and explanations given to us by the Holding Company's Management, these unaudited interim financial results and other financial information are not material to the Group.

Our conclusion is not modified in respect of this matter.

**For Rattan Kaur & Associates**
Chartered Accountants
FRN: 022513N

RATTAN KAUR & ASSOCIATES
Chandigarh
FRN 022513N
CHARTERED ACCOUNTANTS

**(Rattan Kaur)**
Partner
M. No. 513530

**Place:** Gurugram
**Date:** August 10, 2026
**UDIN: 26513530IHVLHQ7651**

Ind-Swift Laboratories Limited
One World One Health One Ind-Swift

**IND-SWIFT LABORATORIES LIMITED**

**Regd Office : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh-160101**

**STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026**

**CIN L24232CH1995PLC015553**

| | | | | Rs. In Lakhs |
|---|---|---|---|---|
| | CONSOLIDATED | | | |
| **Particulars** | **Quarter Ended 30.06.2026** | **Quarter Ended 31.03.2026** | **Quarter Ended 30.06.2025** | **Year Ended 31.03.2026** |
| | **UnAudited** | **Audited** | **Unaudited** | **Audited** |
| **Income from Operations:** | | | | |
| Revenue from operations | 19145.39 | 17762.98 | 15832.24 | 64913.61 |
| Other Income | 765.20 | 222.17 | 899.33 | 4696.72 |
| **Total Income** | **19910.59** | **17985.15** | **16731.57** | **69610.33** |
| **EXPENSES:** | | | | |
| a Cost of Materials Consumed | 8175.83 | 7945.43 | 6539.95 | 27680.30 |
| b.Purchase of stock in Trade | 1350.38 | 775.97 | 866.23 | 3816.13 |
| c.( Increase) /decrease in FG,WIP & stock in trade | (1692.87) | (2016.36) | (97.32) | (2693.47) |
| d. Employee benefit | 3956.06 | 3777.86 | 3253.13 | 13853.41 |
| e.Finance Costs | 70.52 | (243.47) | 115.14 | 140.49 |
| f. Depreciation | 758.31 | 811.64 | 667.68 | 3060.59 |
| g. Other expenditure | 4012.63 | 5052.19 | 4351.35 | 17576.57 |
| **TOTAL EXPENSES** | **16630.86** | **16103.26** | **15696.16** | **63434.02** |
| **Profit(loss) before exceptional Items and Tax** | **3279.73** | **1881.89** | **1035.41** | **6176.31** |
| Exceptional Items (Income) /loss | 23.58 | 515.24 | 0.00 | 1100.64 |
| **Profit(loss) before Tax (After exceptional items)** | **3256.15** | **1366.65** | **1035.41** | **5075.66** |
| **Tax Expenses :-** | | | | |
| Current Tax | 799.92 | 225.26 | 170.58 | 1313.11 |
| Mat credit Utilisation | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax | (0.78) | (540.15) | 0.00 | (540.15) |
| **Profit/ (Loss) after tax and before share of** | **2457.01** | **1681.55** | **864.83** | **4302.71** |
| **Share of profit (loss) in joint venture** | 11.40 | 0.62 | 12.62 | 9.77 |
| **Profit (+)/ Loss (-) for the period from continuing operations** | **2468.41** | **1682.16** | **877.45** | **4312.48** |
| **Profit (+)/ Loss (-) from discontinuing operations** | 0.00 | 0.00 | 0.00 | 0.00 |
| **Tax Expense of discounting operations** | 0.00 | 0.00 | 0.00 | 0.00 |
| **Profit (+)/ Loss (-) from discontinuing operations(after Tax)** | 0.00 | 0.00 | 0.00 | 0.00 |
| **Net Profit /( Loss) for the period after tax & Exceptional items)** | **2468.41** | **1682.16** | **877.45** | **4312.48** |
| | | | | |
| **Other Comprehensive Income** | | | | |
| A) Items that will not be reclassified to P/L A/c | 0.00 | 87.45 | 0.00 | 87.45 |
| B) items that will be reclassified into P/L A/c | (8.23) | 377.89 | 0.00 | 377.89 |
| **Other Comprehensive Income ( Loss) for the period , net of Tax** | **(8.23)** | **465.34** | **0.00** | **465.34** |
| **Total Comprehensive Income for the Period** | **2476.64** | **1216.82** | **877.45** | **3847.14** |
| Paid up Equity Share Capital(Face Value of Rs. 10/- per Share) | 8683.66 | 8161.16 | 8161.16 | 8683.66 |
| Reserve excluding revaluation reserves | | | | 138402.35 |
| EPS (of Rs. 10/- each) (Not annualised) | | | | |
| Basic | 2.84 | 2.01 | 1.28 | 5.16 |
| Diluted | 2.84 | 1.96 | 1.17 | 5.03 |

**FOR IND-SWIFT LABORATORIES LIMITED**

Navrattan

Ind-Swift Laboratories Ltd.

**NAVRATTAN MUNJAL**
**CHAIRMAN**

**Date: 10-08-2026**
**Place: Panchkula**

**Regd. Office:** SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101, INDIA
0172-2730503, 2730920, 5061851-53 info@indswiftlabs.com www.indswiftgroup.com
CIN No. L24232CH1995PLC015553
Follow us:

For verifying authenticity of this letter, please reach us by sending copy of same on hr.ho@indswiftlabs.com

**Notes: -**

1. During the quarter ended 30th June, 2026, the company has achieved an EBITDA of Rs. 33.32 Crores and earned a Standalone Net Profit of Rs. 24.44 Crores as compared to the EBITDA of Rs. 8.44 Crores and Standalone Net Profit of Rs. 8.12 Crores during the corresponding quarter of previous financial year.

2. The above Un-Audited Standalone and Consolidated Financial Results have been prepared considering the requirements of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended. These results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 10th August, 2026. The above results have been subjected to limited review by the statutory auditors of the Company. The reports of the statutory auditors are unqualified.

3. The Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30.06.2026 have been prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

4. The figures for the quarter ended March 31, 2026 were the balancing figures between audited figures in respect of full financial year and the year-to-date figures upto the third quarter of the previous financial year.

5. Exceptional items for the quarter ended 30th June, 2026 is Rs. 23.58 Lakhs whereas for 31st March, 2026 comprise of Rs. 515.24 Lakhs and for the financial year ended 31st March, 2026 of Rs. 1100.64 Lakhs, towards balances written back/written off (net) on account of amounts no longer payable/receivable.

6. The Company has invested the available surplus funds in various investment avenues which is regularly being monitored by the Investment Committee duly constituted by the Board of Directors of the Company.

7. The Consolidated financial results include the financial results of the parent company, Ind-Swift Laboratories Limited and the financial results of the following subsidiaries/Joint Venture:
    a) Ind-Swift Laboratories Inc., USA (Subsidiary)
    b) Fortune (India) Constructions Limited (Subsidiary)
    c) Indis Healthcare LLP (Joint Venture)
    d) MJM Remedies Private Limited (Subsidiary)
    e) ISLL Middle East LLC-FZ (Subsidiary)
    f) Ind Swift India Limited Kenya (Subsidiary)
    g) Capital Strikers LLP (Joint Venture)

    Ind-Swift Laboratories Limited and its subsidiaries are collectively referred to as 'the Group'.

8. No adjustment has been made in respect of Deferred Taxes as per Ind-AS 12, as the same would be provided at year end.

9. During the quarter under review the Company has not issued any Non-Convertible Debt Securities.

10. The previous period figures have been re-grouped and re-classified wherever necessary.

11. The Company is exclusively in the Pharmaceutical Business segment.

For **Ind-Swift Laboratories Limited**

Navrattan

Ind-Swift Laboratories Ltd.

**Navrattan Munjal**
**Chairman**

**Place: Panchkula**
**Date: 10th August, 2026**

**Ind-Swift Laboratories Limited**
*Registered Office*
SCO 850, Shivalik Enclave,
NAC Manimajra, Sector 13,
Chandigarh – 160101 INDIA
info@indswiftlabs.com
0172-2730503, 2730920, 5061851-53
CIN No. L24232CH1995PLC015553

**Annexure II**

| S. No. | Particulars | Details |
|---|---|---|
| **1.** | The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year | The proposed transaction pertains to sale of a non-operational land parcel and does not relate to sale/ disposal of any operational undertaking. Accordingly, disclosure related to turnover/ revenue/ income contribution is not applicable. |
| **2.** | Name(s) of parties with whom the agreement is entered | **Nitin Jindal & Others** |
| **3.** | Details of land | Land admeasuring 40 Bighas located at Village Behra, Derabassi, Punjab |
| **4.** | Date on which the agreement for sale has been entered into | **August 10, 2026** |
| **5.** | The expected date of completion of sale / disposal | Over a period of 9 (Nine) months, subject to the terms and conditions of the agreement |
| **6.** | Consideration received from such sale/disposal | Agreed consideration of **₹17.50 Crore** shall be received over a period of 9 (Nine) months |
| **7.** | Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/ group companies. If yes, details thereof | The Buyer does not belong to the promoter/ promoter group/ group companies. |
| **8.** | Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms length" | The transaction does not fall under the ambit of Related Party Transaction(s). |
| **9.** | Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations. | This sale of property is not part of a Scheme of Arrangement. Further, the sale of the said land does not attract the terms of regulation 37A of the LODR Regulations, as it does not constitute an undertaking or substantially the whole of the undertaking of the Company under section 180 (1)(a) of the Companies Act, 2013. |
| **10.** | Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale. | NA |

PARDEEP VERMA

Digitally signed by PARDEEP VERMA
Date: 2026.08.10
19:03:00 +05'30'